von Willebrand disease

News

Incyte gobbles up Star's Vega haematology unit in $2bn deal

Incyte has agreed to buy Star Therapeutics' Vega subsidiary for $1.25bn upfront, adding a late-stage drug candidate for bleeding disorder VWD.

News

Takeda’s bleeding disorder drug Veyvondi backed for NHS use

NHS England has recommended that patients with von Willebrand disease (VWD) be treated with Takeda’s Veyvondi, making it the first and only medicine backed for what is the most common inher

News

Shire's von Willebrand disease therapy Veyvondi approved in ...

The European Commission has approved Shire’s Veyvondi for treatment of the bleeding disorder von Willebrand disease (VWD).

Incyte gobbles up Star's Vega haematology unit in $2bn deal

Takeda’s bleeding disorder drug Veyvondi backed for NHS use

Shire's von Willebrand disease therapy Veyvondi approved in ...

ESC26: Isomab safety evidence on blood vessel growth for CAD

Discover a new era of healthcare panel engagement: Grounded ...

Editor's Picks